Integrated antibody discovery solution for multi-pass transmembrane target Speaker: Dr. Li Chen, Sr. Director, Biologics Discovery Dept. Date: Nov. 28 th, 2023 Time: 14:00-15:00 (GMT+9) Watch now Speaker Biography Dr. Chen Li is the Sr. Director of Biologics Discovery Department of GenScript ProBio. After obtaining his doctorate in immunology from the University of Massachusetts School of medicine, he joined GenScript in 2015 and has been responsible for antibody drug discovery platform for the past seven years. He has more than 200 project experience in antibody drug discovery and Engineering innovation optimization, as well as three patents related to biopharmaceutical discovery. Topic Background GPCR family is a one of those popular drug target in recent years. However, due to its natural of multi-pass transmembrane structure, it is considered as one of most the challenging type to develop therapeutic antibodies. DNA and whole cell immunization are commonly used to generate antibody leads against GPCR target, but the intrinsic feature of these antigens lead to extremely low hit rate. In this webinar, Dr. Li Chen will introduce a mRNA-based immunization, coupled with high throughput hybridoma screening approach, and demonstrate its advantage over traditional approach. Topic Abstract Review of clinical progress for anti-GPCR therapeutic antibody Integrated solution of therapeutic antibody discovery against GPCR target Case study of anti-GPCR antibody drug candidates
Latest WebinarsCost Reduction Strategies in Clinical Stage Process Optimization for BiologicsAccelerated therapeutic antibody discovery via ProSpeed™ single B cell platformIntegrated antibody discovery solution for multi-pass transmembrane targetADC One-stop Solution: Discovery, Development and ManufacturingFind More Therapeutic Antibody Categories